ASH 2022 | Phase I/Ib safety study of PRGN-3006 UltraCAR-T in patients with R/R CD33-positive AML & HR-MDS
Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of a Phase I/Ib safety study of PRGN-3006 UltraCAR-T in patients with relapsed/refractory (R/R) CD33-positive acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) (NCT03927261). Dr Bejanyan briefly explains the mechanism of action and rapid manufacturing of this agent, and then goes on to highlight findings from this study. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Medexus Pharmaceuticals: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CareDX Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
